IL13 and chronic rhinosinusitis with nasal polyps: Dupilumab, an anti-IL-4Rα monoclonal antibody inhibiting IL-4 and IL-13 signaling, was the first biological drug approved in 2019 by the FDA as an adjunct therapy to intra-nasal corticosteroids in adult patients suffering from CRSwNP [7,8].